- Current guidelines recognize 3 highly effective ways to screen for cervical cancer: cytology, cotesting, and primary human papillomavirwus (HPV) testing.
- Clinical HPV testing detects the presence of high-risk HPVs that account for nearly all cervical cancers.
- HPV-based screening is more sensitive than cytology and allows for longer intervals between screenings.
- Cotesting offers little advantage over primary HPV testing and comes at greater cost.
- Disparities in cervical cancer incidence can be countered by screening using any guideline-supported modality with evidence-based management of abnormal results.